F-star CEO: Revamped Merck KGaA Pact Is First Step In New Corp Direction
F-star CEO tells Scrip reconfiguring biotech’s pact with Merck KGaA on oncology asset FS118 is UK group’s first big move towards a wholly owned portfolio strategy.
You may also be interested in...
Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.
The German company is predicting sales in mid-triple-digits in 2019 for Mavenclad, its multiple sclerosis drug which has just been launched in the US, and has highlighted more promising MS data for its BTK inhibitor evobrutinib.
AstraZeneca has vowed to slash its carbon emissions to zero by 2025 and ensure its entire value chain is carbon negative by 2030. It will spend up to $1bn to do so.